Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
MORRISTOWN, N.J., April 05, 2016 -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that Doug Drysdale, Chairman and Chief Executive Officer, and Sanjay Patel, Chief Financial Officer, will present at Needham & Company’s 15th Annual Healthcare Conference, as follows.
| Date: | Wednesday, April 13, 2016 | |
| Time: | 3:00 PM EDT | |
| Location: | New York, NY - Westin New York Grand Central Hotel | |
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its Pernix sales force and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
Investor Relations Sanjay Patel, (800) 793-2145 ext. 1009 Chief Financial Officer [email protected] Matthew P. Duffy, 212.915.0685 LifeSci Advisors, LLC [email protected]
